HER-2-positive, hormone
receptor-negative breast cancer patients have a high risk of
treatment failure after chemotherapy -- and the most common
site of cancer recurrence after treatment failure is the brain,
Mayo Clinic researchers reported at the San Antonio Breast
Cancer Symposium.

More: - Brought to my attention by